Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 18/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 7/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.54 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | ULK1 | O75385 | 1/20 | 0.54 |
| ▸ | ERN1 | O75460 | 1/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | KRAS | P01116 | 1/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | YES1 | P07947 | 1/20 | 0.54 |
| ▸ | LYN | P07948 | 1/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.54 |
| ▸ | HCK | P08631 | 1/20 | 0.54 |
| ▸ | FGR | P09769 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194335 | 0.86 | BRAF (0.59) | BRAFNR1I2RIPK2PLK4EPHB6 | |
| SCHEMBL26361980 | 0.85 | BRAF (0.52) | BRAFNR1I2RIPK2PLK4EPHB6 | |
| SCHEMBL30586522 | 0.85 | BRAF (0.49) | BRAFNR1I2RIPK2PLK4EPHB6 | |
| SCHEMBL26361248 | 0.85 | BRAF (0.49) | BRAFNR1I2RIPK2PLK4EPHB6 | |
| SCHEMBL30586583 | 0.84 | BRAF (0.52) | BRAFNR1I2RIPK2PLK4EPHB6 | |
| SCHEMBL26362068 | 0.84 | BRAF (0.52) | BRAFNR1I2RIPK2PLK4EPHB6 | |
| SCHEMBL26362585 | 0.84 | BRAF (0.51) | BRAFNR1I2RIPK2PLK4EPHB6 | |
| SCHEMBL26363412 | 0.84 | BRAF (0.51) | BRAFNR1I2RIPK2PLK4EPHB6 | |
| SCHEMBL2192092 | 0.83 | BRAF (0.54) | BRAFNR1I2RIPK2PLK4EPHB6 | |
| SCHEMBL26361003 | 0.83 | BRAF (0.51) | BRAFNR1I2RIPK2PLK4EPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499634-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | Nikang Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119053595-A | Sulfonylamino derivatives as cyclin dependent kinase 2 inhibitors | 尼坎治疗公司 | 2024-11-29 | — | — | CN | disclosed |
| WO-2023192801-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | CDK2, CCNK, CCNI | BRAF 159/4885NR1I2 1332/4885RIPK2 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.